SpectraCure AB (DE:2OK)
FRANKFURT:2OK
2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range€0.00 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€6.72M
Enterprise Value€42.95M
Total Cash (Recent Filing)€16.59M
Total Debt (Recent Filing)€2.19M
Price to Earnings (P/E)―
Beta-81.01
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding570,602,840
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt-to-equity (≈0.03) materially reduces solvency and interest burden, giving management optionality to fund development through equity or partnerships rather than servicing debt. This structural balance-sheet strength extends runway flexibility during multi-year clinical commercialization efforts.
Focused Therapeutic PlatformA platform product (IDOSE®) that integrates fiber-optic light delivery with real-time dosing control is a durable commercial asset if validated. Platform-centric technology can enable multiple indications and recurring device/procedure revenues, strengthening long-term growth prospects once clinical and regulatory milestones are met.
Aligned With Minimally Invasive Oncology TrendThe company's focus on minimally invasive cancer therapies aligns with a structural healthcare shift toward less invasive, outpatient procedures. This long-term trend supports adoption potential, favorable reimbursement dynamics, and partnerships with specialist centers if clinical efficacy and safety are demonstrated.
Bears Say
No Meaningful RevenueZero reported revenue indicates no commercial validation or recurring sales to offset fixed costs. Over a multi-quarter horizon this creates sustained reliance on financing, delays path to operating leverage, and elevates execution risk because clinical success still must translate into scalable commercial uptake.
Sustained Cash BurnConsistent negative operating cash flow (~-24m in 2025) and negative free cash flow signal ongoing funding needs. Over 2–6 months this structural cash drain increases dilution risk, constrains R&D/ commercialization spending flexibility, and forces management to prioritize capital raises or partnerships over organic growth.
Large Recurring Losses And Equity ErosionMaterial net losses (~-56m in 2025) and declining equity with deeply negative ROE indicate shareholder value dilution and persistent unprofitability. Structurally, continued losses limit ability to self-fund commercialization, raise governance and investor scrutiny, and may force accelerated dilution or restrictive financing terms.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €6.72M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is Aug 14, 2026 which is in 65 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on May 27, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.